Glaxo’s Vaccines Division Outperforms

“The vaccines division continues to deliver, and Investors will be buoyed by management increasing guidance for the financial year”. In Morningstar, Edentree’s Ketan Patel discusses the reasoning behind GlaxoSmithKline’s better-than-expected growth in 2019.

top